.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Express Scripts
Merck
Teva
Cipla
UBS
Healthtrust
Dow
Accenture
Fish and Richardson
Cantor Fitzgerald

Generated: September 23, 2017

DrugPatentWatch Database Preview

Fluocinonide - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for fluocinonide and what is the scope of fluocinonide patent protection?

Fluocinonide
is the generic ingredient in five branded drugs marketed by Taro, Novel Labs Inc, G And W Labs Inc, Fougera Pharms, Cnty Line Pharms, Teva, Teva Pharms, Fougera Pharms Inc, Fougera, Perrigo Israel, Medicis, Glenmark Generics, and Perrigo New York, and is included in thirty-three NDAs. There are four patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Fluocinonide has eleven patent family members in nine countries.

There are nine drug master file entries for fluocinonide. Thirty suppliers are listed for this compound.

Summary for Generic Name: fluocinonide

Tradenames:5
Patents:4
Applicants:13
NDAs:33
Drug Master File Entries: see list9
Suppliers / Packagers: see list30
Bulk Api Vendors: see list44
Clinical Trials: see list8
Patent Applications: see list5,671
Therapeutic Class:Hormonal Agents, Stimulant/Replacement/Modifying (Adrenal)
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:fluocinonide at DailyMed

Pharmacology for Ingredient: fluocinonide

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cnty Line Pharms
LIDEX
fluocinonide
SOLUTION;TOPICAL018849-001Apr 6, 1984ATRXYesNo► Subscribe► Subscribe► Subscribe
Novel Labs Inc
FLUOCINONIDE
fluocinonide
OINTMENT;TOPICAL207538-001Jul 31, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Novel Labs Inc
FLUOCINONIDE
fluocinonide
SOLUTION;TOPICAL206003-001Jul 21, 2017ATRXNoNo► Subscribe► Subscribe► Subscribe
Glenmark Generics
FLUOCINONIDE
fluocinonide
CREAM;TOPICAL091282-001Jul 14, 2014ABRXNoNo► Subscribe► Subscribe► Subscribe
Medicis
VANOS
fluocinonide
CREAM;TOPICAL021758-001Feb 11, 2005ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Taro
FLUOCINONIDE
fluocinonide
GEL;TOPICAL074935-001Jul 29, 1997ABRXNoYes► Subscribe► Subscribe► Subscribe
Cnty Line Pharms
LIDEX
fluocinonide
CREAM;TOPICAL016908-002Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe► Subscribe
Cnty Line Pharms
LIDEX-E
fluocinonide
CREAM;TOPICAL016908-003Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe► Subscribe
Taro
FLUOCINONIDE
fluocinonide
CREAM;TOPICAL200734-001Jul 14, 2014ABRXNoNo► Subscribe► Subscribe► Subscribe
Cnty Line Pharms
LIDEX
fluocinonide
OINTMENT;TOPICAL016909-002Approved Prior to Jan 1, 1982ABRXYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: fluocinonide

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Cnty Line Pharms
LIDEX
fluocinonide
CREAM;TOPICAL016908-002Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Cnty Line Pharms
LIDEX
fluocinonide
OINTMENT;TOPICAL016909-002Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Cnty Line Pharms
LIDEX
fluocinonide
CREAM;TOPICAL016908-002Approved Prior to Jan 1, 1982► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: fluocinonide

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,217,422Compositions and methods for enhancing corticosteroid delivery► Subscribe
7,771,733Compositions and methods for enhancing corticosteroid delivery► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: fluocinonide

Country Document Number Estimated Expiration
China1617730► Subscribe
World Intellectual Property Organization (WIPO)03055445► Subscribe
Japan2005524614► Subscribe
Australia2002360589► Subscribe
Israel162581► Subscribe
Japan2010280689► Subscribe
MexicoPA04006014► Subscribe
European Patent Office1465636► Subscribe
Canada2471041► Subscribe
European Patent Office2363150► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Citi
McKinsey
Teva
AstraZeneca
Cerilliant
Julphar
Deloitte
Johnson and Johnson
Colorcon
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot